Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AANAmerican Academy of Neurology
ADAAntidrug antibody
AEAdverse event
AHFSAmerican Hospital Formulary Service
aINCATAdjusted Inflammatory Neuropathy Cause and Treatment disability score
ALTAlanine aminotransferase
ANAAntinuclear antibody
ASTAspartate aminotransferase
ATCAnatomical Therapeutic Chemical
BLABiologics License Application
CAGRCompound annual growth rate
CDA-AMCCanada's Drug Agency (L'Agence des médicaments du Canada)
CH50Total hemolytic complement activity
CHOChinese hamster ovary
CIConfidence interval
CIDPChronic inflammatory demyelinating polyneuropathy
CMAPCompound muscle action potential
CMTCharcot-Marie-Tooth disease
CNTN1Contactin-1
CSFCerebrospinal fluid
CTCAECommon Terminology Criteria for Adverse Events
DILDrug-induced lupus
dsDNADouble-stranded DNA
DSMBData and safety monitoring board
EAGExternal assessment group
EANEuropean Academy of Neurology
EFNSEuropean Federation of Neurological Societies
EQ-5DEuroQol 5-dimension questionnaire
EQ-5D-3LEuroQol 5-dimension, 3-level questionnaire
EQ-5D-5LEuroQol 5-dimension, 5-level questionnaire
EQ-VASEuroQol visual analog scale
FACITFunctional Assessment of Chronic Illness Therapy
FcRnNeonatal Fc receptor
FDAU.S. Food and Drug Administration
FSSFatigue Severity Scale
GBSGuillain-Barré syndrome
gMGGeneralized myasthenia gravis
HADSHospital Anxiety and Depression Scale
HCPCSHealthcare Common Procedure Coding System
HRQoLHealth-related quality of life
I-RODSInflammatory Rasch-built Overall Disability Scale
IC90Concentration producing 90% inhibition
IC95Concentration producing 95% inhibition
ICD-10International Classification of Diseases, Tenth Revision
ICERIncremental cost-effectiveness ratio; Institute for Clinical and Economic Review
ICUIntensive care unit
IGImmunoglobulin
IgGImmunoglobulin G
IGIVImmune globulin intravenous
INCATInflammatory Neuropathy Cause and Treatment
INNInternational nonproprietary name
ISRInjection site reaction
IVIntravenous
IVIGIntravenous immunoglobulin
IVIgIntravenous immunoglobulin
IVMPIntravenous methylprednisolone
MACMembrane attack complex
MADMultiple ascending dose
MCIDMinimal clinically important difference
MMNMultifocal motor neuropathy
MRCMedical Research Council
MRC-SSMedical Research Council sum score
MuSKMuscle-specific kinase
NF155Neurofascin-155
NHSNational Health Service
NICENational Institute for Health and Care Excellence
NPRSNumeric Pain Rating Scale
OLEOpen-label extension
ONLSOverall Neuropathy Limitations Scale
OROdds ratio
PDPharmacodynamics
PEPlasma exchange
PKPharmacokinetics
PLEXPlasma exchange
PNSPeripheral Nerve Society
POEMSPolyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes syndrome
PPVPositive predictive value
Q2WEvery 2 weeks
QALYQuality-adjusted life-year
RCTRandomized controlled trial
REMSRisk Evaluation and Mitigation Strategy
RRRate ratio
SADSingle ascending dose
SAESerious adverse event
SCSubcutaneous
SCIGSubcutaneous immunoglobulin
SCIgSubcutaneous immunoglobulin
SDStandard deviation
SECU.S. Securities and Exchange Commission
SF-3636-Item Short Form Health Survey
SLESystemic lupus erythematosus
SoCStandard of care
TEAETreatment-emergent adverse event
ULNUpper limit of normal
VASVisual analog scale
VEGFVascular endothelial growth factor
WHOWorld Health Organization
WPAIWork Productivity and Activity Impairment questionnaire
YTETyrosine, threonine, and glutamate substitutions in the Fc domain that extend half-life